Zhihong Fang

Zhihong Fang


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
YZYining Zhang
Yining Zhang
YHYuqing Huang
Yuqing Huang
YHYan Hong
Yan Hong
ZLZhijuan Lin
Zhijuan Lin
JZJie Zha
Jie Zha
BXBing Xu
Bing Xu

1 August 2017 in Leukemia Research
Verified
Journal Article
Closed access
HYHui Yang
Hui Yang
ZFZhihong Fang
Zhihong Fang
YWYue Wei
Yue Wei
ZBZachary S. Bohannan
Zachary S. Bohannan
IGIrene Gañán-Gómez
Irene Gañán-Gómez
GGGuillermo Garcia-Manero
Guillermo Garcia-Manero

14 September 2020 in Trials
Verified
Journal Article
Open access
PDF file
HYHongyu Yue
Hongyu Yue
SZShuang Zhou
Shuang Zhou
LCLiming Chen
Liming Chen
XYXuan Yin
Xuan Yin
SLShanshan Li
Shanshan Li
SXShifen Xu
Shifen Xu
Background: Cancer-related insomnia (CRI) is one of the most prevalent complaints among cancer survivors and severely impairs patients’ quality of life. As a popular non-pharmacological alternative treatment, acupuncture provides a good clinical curative effect on insomnia. The aim of this trial is to evaluate efficacy and safety of electro-acupuncture on insomnia in patients with lung cancer.Method: This is a protocol for a multicenter randomized single-blinded sham-controlled trial. We will randomly assign 252 eligible patients with lung cancer-related insomnia into two groups at a ratio of 1:1, the treatment group (EA) and the control group (sham EA). All treatment will be given 3 times per week for 8 weeks, and a 12-week follow-up will be conducted. The primary outcome will be measured by the Pittsburgh Sleep Quality Index (PSQI). The secondary outcomes will include sleep parameters recorded from the actigraphy, scores from Quality of Life Questionnaire Core-30 (QLQ-C30), and Patient Health Questionnaire-9 (PHQ-9). All adverse effects during the trial will be assessed by the Treatment Emergent Symptom Scale (TESS). All analyses will be based on ITT principle and performed with the statistical software SPSS (version 24.0) byttest, rank-sum test, chi-square, and so on. A two-sided significance level will be set at 5%.Discussion: This large-sample trial protocol will evaluate the efficacy of electro-acupuncture on insomnia in patients with lung cancer. This protocol, if proven to be effective, will contribute to filling the gap in treatment options in the CRI field and provide a promising intervention for insomnia in lung cancer survivors.Trial registration: ChiCTR ChiCTR1900026395. Registered on 8 October 2019,http://www.chictr.org.cn/showproj.aspx?proj=44068

1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
SZSufang Zhang
Sufang Zhang
WCWanqing Chen
Wanqing Chen
YWYuli Wang
Yuli Wang
JWJianchun Wu
Jianchun Wu
LXLili Xu
Lili Xu
YLYan Li
Yan Li
Chinese herbal Fu‐Zheng‐Qu‐Xie (FZQX) prescription has been found to improve the immune function and survival of patients with early‐stage lung cancer. However, the therapeutic efficacy needs to be evaluated objectively, and the precise mechanism remains unclear. In the present study, a double‐center, prospective cohort study was carried out to assess the clinical efficacy of the FZQX prescription in preventing the recurrence and metastasis of postoperative early‐stage lung adenocarcinoma. Our results indicated that the FZQX prescription could significantly reduce the 3‐year postoperative recurrence rate and improve the life quality. Moreover, the peripheral blood indices showed that the positive immune index (CD4+T/CD8+T) increased and the negative immune indices (CD8+T, Myeloid‐derived suppressor cells (MDSCs), Treg) decreased after treatment with the FZQX prescription. Since the positive regulatory effect of the FZQX prescription on immune function, a series of experiments were conducted to verify the tumor‐suppressive effect and elucidate the underlying mechanisms. Through the MDSC clearance xenograft model, we confirmed that the FZQX prescription could effectively suppress tumor growth with lesser side effects in vivo, and MDSCs may be involved in the biological process of the FZQX prescription’s intervention in lung cancer progression. By establishing the coculture system of MDSCs/LLC to simulate the immune microenvironment of lung cancer, the tumor suppression effect of the FZQX prescription was further validated by in vitro experiments. Besides, it was confirmed that the FZQX prescription could regulate MDSCs to remodel the immunosuppressive tumor microenvironment, thus exerting its preventive effect on relapse of lung cancer. Finally, the pathway activator and inhibitor were further used to explore the potential molecular mechanism. Results demonstrated that the IL‐1β/NF‐κB signaling pathway was one of the critical signaling pathways of FZQX prescription regulating MDSCs to prevent the recurrence and metastasis of lung adenocarcinoma.

23 August 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
LXLi-Li Xu
Li-Li Xu
SZSu-Fang Zhang
Su-Fang Zhang
YWYu-Li Wang
Yu-Li Wang
YLYing-Bin Luo
Ying-Bin Luo
ZFZhihong Fang
Zhihong Fang
YLYan Li
Yan Li
Objective. To explore the efficacy of long-term use of Chinese herbal medicine (CHM) on survival time of lung cancer. Methods. We conducted a retrospective cohort study on lung cancer patients. A propensity score matching (PSM) was performed to balance the covariates. Progression-free survival (PFS) was the primary endpoint and overall survival (OS) was the secondary endpoint. Patients who received CHM therapy from the initial date of diagnosis of lung cancer were included in the CHM group. Patients who were not treated with CHM during the same interval were categorized in the control group. A Cox regression model was used to explore the prognostic factors related to lung cancer. Hazard ratios of different subgroups were also analyzed. Results. A total of 1134 patients were included in our study: 761 patients were in the CHM group and 373 patients were in the control group. After PSM, the mPFS and mOS in the CHM group were 70.4 months and 129.1 months, respectively, while the mPFS and mOS in the control group were 23.8 months and 99.7 months, respectively. The results of survival analysis on each stage demonstrated that patients may benefit from the long-term CHM treatment especially for patients with early stage. One-year to ten-year progression-free survival rates in the CHM group were higher than those in the control group ( ). COX multivariate regression analysis indicated that CHM treatment, female, low age at diagnosis, early tumor stage, and surgery were independent protective factors against recurrence and metastasis of lung cancer. Subgroup analysis showed that CHM treatment could reduce the risk of recurrence and metastasis in each subgroup ( ). Conclusion. Long-term CHM treatment with the Fuzheng Quxie Formula, which can be flexibly applied in the course of lung cancer treatment, not only has a positive influence on the progression-free survival time of lung cancer patients, but also reduces the risk of recurrence and metastasis of lung cancer.

20 April 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YWYuli Wang
Yuli Wang
NSNingyang Sun
Ningyang Sun
YLYingbin Luo
Yingbin Luo
ZFZhihong Fang
Zhihong Fang
YFYuan Fang
Yuan Fang
YLYan Li
Yan Li
Yu-Ping-Feng (YPF) formula is a classical prescription used for enhancing the bodys immunity function in traditional Chinese medicine (TCM). In clinical practice, the YPF formula has been reported to exhibit antilung cancer and immunomodulatory effect. However, the relationship between them remains unclear. The present study aimed to investigate the antilung cancer effect of the YPF formula and its immune-related mechanisms. The C57BL/6 tumor-bearing mice model was established and randomly divided into the YPF group and the control group. Tumor volume, spleen weight, and survival in both groups were measured and evaluated during 28 days of consecutive intervention. Flow cytometry was used to detect the proportion of immune cell subsets. Myeloid-derived suppressor cells (MDSCs) were induced in vitro from bone marrow cells. After intervention by the YPF formula, CCK-8 and flow cytometry analyses were performed to detect proliferation and apoptosis of MDSCs. A coculture system containing T cells and MDSCs was established to further study the role of MDSCs in the regulation of T-cell subsets proportion by the YPF formula. The expressions of MDSCs-related genes and proteins were detected by RT-PCR and Western blotting. The results showed the YPF formula inhibited tumor growth, reduced spleen weight, and prolonged the survival of mice. Besides, the proportions of MDSCs subsets and Regulatory T (Treg) in the YPF group decreased, whereas those of CD4+T and CD8+T increased both in vitro and in vivo. CCK-8 and flow cytometry demonstrated that the YPF formula could inhibit proliferation and promote apoptosis of MDSCs. The coculture experiments further confirmed that MDSCs served a critical role in regulating the tumor microenvironment by the YPF formula. RT-PCR and Western blotting indicated that the levels of MDSCs activation and proliferation-related proteins and genes were downregulated in the YPF group. Therefore, our results demonstrated that the YPF formula could promote apoptosis and inhibit the proliferation of MDSCs. As a result, the negative regulatory effect on the positive immune cells induced by MDSCs was weakened, thus achieving the antilung cancer effect by remodeling the tumor microenvironment.